A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, aged 7 to 17 years, who fulfill Rome III Criteria for Child/Adolescent Irritable Bowel Syndrome and have symptoms of constipation (IBS-C)
Linaclotide study for children with Irritable Bowel Syndrome- Constipation (IBS-C)
Sponsor: Allergan-Forest Research Institute
Enrolling: Male and Female Patients
Study Length: 12 Weeks
Clinic Visits: 6
IRB Number: AAAQ8246
U.S. Govt. ID: NCT02559817
Contact: Kelly Naranjo: 212-342-4414 / kvn2111@cumc.columbia.edu
Additional Study Information: We are currently recruiting pediatric patients ages 7-17 who suffer from Irritable Bowel Syndrome with Constipation (IBS-C) for our Linaclotide clinical trial. Study will involve 6 visits and will last anywhere from 10-12 weeks after the patient qualifies.
This study is closed
Investigator
Julie Khlevner, MD
Do You Qualify?
Is child between the ages of 7 -17? Yes No
Does child suffer from Irritable Bowel Syndrome with Constipation (IBS-C)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Kelly Naranjo
kvn2111@cumc.columbia.edu
212-342-4414
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE